D-0693-2026 Class II Ongoing

Recalled by Blaine Labs Inc — Santa Fe Springs, CA

FDA drug recall D-0693-2026 was initiated by Blaine Labs Inc on Apr 8, 2026 and is designated Class II. Reason for recall: CGMP Deviations: product manufactured in the same facility under the same conditions as the product found to be contaminated The recall status is ongoing. Affected quantity: 519 - 1 oz bottles.

Recall details

Product Type
Drugs
Report Date
Jul 8, 2026
Initiation Date
Apr 8, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
519 - 1 oz bottles

Product description

TRIFLUENT PHARMA TRIDERGEL Wound Care Gel, (Benzalkonium Chloride 0.1%), 1.0 fl oz, (29.6 mL) bottle with long pointy cap, Manufactured for: Trifluent Pharma, LLC. San Antonio, TX 78213. NDC 73352-520-01.

Reason for recall

CGMP Deviations: product manufactured in the same facility under the same conditions as the product found to be contaminated

Distribution pattern

Nationwide in the USA

Code information

Lot #: BL3435, Exp. 11/06/26

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0693-2026
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0693-2026. Report a data issue: hello@regdatalab.com.